Centiva Capital’s Bionano Genomics BNGO Stock Holding History

Centiva Capital’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-26	Closed	-$85K	–	1216
2021 Q3	$85K	Sell	26 -26	-50%	-$90.9K	0.01%	1063
2021 Q2	$229K	Buy	+52	New	+$205K	0.01%	1161

Other funds holding BNGO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Centiva Capital's BNGO Position: Q4 2021 in Review

Centiva Capital sold out of Bionano Genomics (BNGO) in Q4 2021, closing a stake of 26 shares — an estimated $85K sold.

Centiva Capital first reported a position in BNGO in Q2 2021 and held it in 2 quarters. The position peaked at $229K in Q2 2021. 149 funds tracked by Wall St. Rank hold BNGO as of Q4 2021.

Centiva Capital reported no remaining Bionano Genomics position as of Q4 2021 after selling out during the quarter.
Centiva Capital sold 26 Bionano Genomics shares in Q4 2021, an estimated $85K.
Centiva Capital first reported a position in Bionano Genomics in Q2 2021 and held it in 2 quarters.
Centiva Capital's Bionano Genomics position peaked at $229K in Q2 2021.
149 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2021.

Based on Centiva Capital's 13F filing for Q4 2021, filed 14 Feb 2022.